Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.42 |
| ▸ | CES2 | O00748 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | PPARD | Q03181 | 5/20 | 0.33 |
| ▸ | PPARA | Q07869 | 5/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28526149 | 0.92 | CES2 (0.46) | CES1CES2ALDH1A1TSHRPPARG | |
| SCHEMBL28891396 | 0.90 | CES2 (0.45) | CES1CES2ALDH1A1TSHRPPARG | |
| SCHEMBL2954775 | 0.86 | — | — | |
| Methacrylic Acid SCHEMBL7948425 | 0.83 | ALDH1A1 (0.46) | CES1CES2ALDH1A1TSHRALOX15 | |
| SCHEMBL6916133 | 0.82 | CES1 (0.46) | CES1CES2ALDH1A1TP53TSHR | |
| Butane SCHEMBL11085259 | 0.82 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL1298659 | 0.80 | CES1 (0.44) | CES1CES2ALDH1A1TP53TSHR | |
| SCHEMBL198129 | 0.80 | CES1 (0.44) | CES1CES2ALDH1A1TP53TSHR | |
| SCHEMBL10579259 | 0.78 | TSHR (0.42) | CES1CES2ALDH1A1TP53TSHR | |
| SCHEMBL1514197 | 0.78 | CES1 (0.42) | CES1CES2ALDH1A1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111334240-A | Reactive polyurethane hot melt adhesive and preparation method and application thereof | 北京华腾新材料股份有限公司 | 2020-06-26 | — | — | CN | claimed |
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| CN-107007871-B | Folic acid-phosphorylcholine oligomer-modified graphene oxide and preparation method and application thereof | 南京大学 | 2020-09-08 | — | — | CN | disclosed |
| CN-111334240-A | Reactive polyurethane hot melt adhesive and preparation method and application thereof | 北京华腾新材料股份有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10022456-B2 | Reversibly masked polymers | Arrowhead Pharmaceuticals, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2017-01-26 | — | — | US | disclosed |
| US-9487556-B2 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | Arrowhead Pharmaceuticals, Inc. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-3030244-A1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | Arrowhead Research Corporation (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20150273081-A1 | Reversibly Masked Polymers | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2015-10-01 | — | — | US | disclosed |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
| CN-100419007-C | Ambient cure coating and coated rubber products formed therefrom | LORD CORP (US) | 2008-09-17 | — | — | CN | disclosed |
| CN-1671779-A | Ambient cured coatings and coated rubber products therefrom | LORD CORP (US) | 2005-09-21 | — | — | CN | disclosed |
| US-6568997-B2 | Forming a passivating layer copper oxide for reducing the reaction of the copper metal with the polishing mixtures; reducing the problem of dishing of copper circuits of semiconductor devices | RODEL HOLDINGS, INC. | 2003-05-27 | — | — | US | disclosed |
| US-20020173241-A1 | CMP polishing composition for semiconductor devices containing organic polymer particles | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. | 2002-11-21 | — | — | US | disclosed |
| US-20020173243-A1 | Polishing composition having organic polymer particles | RODEL HOLDINGS, INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002081584-A1 | POLISHING COMPOSITION HAVING ORGANIC POLYMER PARTICLES | RODEL HOLDINGS, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | CES1 2072/4885CES2 2301/4885ALDH1A1 4683/4885 |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | CES1 2072/4885CES2 2301/4885ALDH1A1 4683/4885 |
| US-20150273081-A1 | Reversibly Masked Polymers | CD47, MSN, EPCAM | CES1 2843/4885CES2 1525/4885ALDH1A1 4496/4885 |
| US-10022456-B2 | Reversibly masked polymers | CD47, MSN, EPCAM | CES1 2843/4885CES2 1525/4885ALDH1A1 4496/4885 |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | HDAC6, CD47, AADAC | CES1 3415/4885CES2 2358/4885ALDH1A1 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.